1 February 2016 in Journal of Molecular and Cellular Cardiology
28 October 2016 in Nutrition Journal
The association between serum selenium level and gestational diabetes mellitus (GDM) is controversial. The aim of our study was to systematically review available literature linking selenium to GDM for a comprehensive understanding of the relationship between serum selenium level and GDM in human. PubMed, The Cochrane Library and Medline were searched for studies published up to August 2016. Manual searches of references of the relevant original studies were carried out. Pooled estimates were measured using the fixed or random effect model. Overall effect was reported in a standard mean difference (SMD). All data were analyzed with Review Manager 5.3 and Stata 12.0. Of 44 references reviewed, seven studies involving 569 patients met our inclusion criteria and contributed to meta-analysis. All the studies were used to evaluate the relationship between serum selenium level and GDM. Selenium level was significantly lower in women with GDM than those without GDM (SMD = −1.17; 95 % CI: −1.98 to −0.35, P = 0.005). Subgroup analysis showed that such trend was consistent within the non-Caucasian population (Asia: SMD = −2.82; 95 % CI: −5.21 to −0.43, P = 0.02; Africa: SMD = −0.56; 95 % CI: −1.07 to −0.05, P = 0.03) and in the third trimester (SMD = −1.78; 95 % CI: −3.04 to −0.52, P = 0.006), but not within the Caucasian population (Europe: SMD = −0.6; 95 % CI: −1.98 to 0.78, P = 0.39) or in the second trimester (SMD = −0.68; 95 % CI: −1.6 to 0.25, P = 0.15). The available evidences suggested that serum selenium level was lower in women with GDM than those with normal glucose tolerance, especially within the non-Caucasian population and in the third trimester. However, well-designed prospective studies are needed to understand dynamic associations between selenium status and GDM risk.
4 September 2024 in Journal of Cardiovascular Translational Research
26 December 2024 in Journal of Cardiovascular Translational Research
6 February 2025 in Medical Engineering & Physics
A coronary atherectomy system (CAS) was developed with a novel burr designed for a two-phase atherectomy procedure: low-speed drilling for lesion crossing and high-speed orbiting to achieve luminal gain, to removal the stenosis in artery. To investigate the CAS mechanism and validate its efficacy and safety. Engineering bench-top testings were conducted to evaluate the burr crossing time, luminal gain, debris size, temperature rise, and grinding force together with in-vivo and ex-vivo swine studies. The bench-top engineering testing results showed that the CAS can expand the calcified lumen diameter from 0.4 to 1.7 mm and the debris size, temperature rise, and grinding force were relatively low and safe. In the in-vivo swine study, the media and internal elastic membrane remained intact. The intima of the artery was removed at the 0-day follow-up and re-growthed at the 30-day follow-up. No abnormal phenomenon in the digital subtraction angiography, blood testing, ECG, and anatomy analysis were found. The ex-vivo study, by inserting a plaque surragate (graphite) into the coronary artery, showed similar efficacy in luminal gain and safety. This study demonstrated the efficacy and safety of CAS device with the novel two-phase burr design.